Management of rheumatologic diseases in pregnancy

International Journal of Clinical Rheumatology

Volumn 7, Issue 5, 2012, Pages 541-558

  Ateka Barrutia, Oier ^a   Nelson Piercy, Catherine ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

management; medications; pre pregnancy counseling; pregnancy; rheumatic diseases

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; BELIMUMAB; BETAMETHASONE; CHLOROQUINE; CLOPIDOGREL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FOLIC ACID; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MEPREDNISONE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TACROLIMUS; TICLOPIDINE; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG;

ANKYLOSING SPONDYLITIS; ANTIPHOSPHOLIPID SYNDROME; BREAST FEEDING; CHRONIC ARTHRITIS; CONGENITAL HEART BLOCK; DERMATOMYOSITIS; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FEMALE FERTILITY; HEALTH CARE MANAGEMENT; HUMAN; HYPERTENSION; INFECTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MIXED CONNECTIVE TISSUE DISEASE; NEWBORN LUPUS ERYTHEMATOSUS; OSTEOPOROSIS; POLYMYOSITIS; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE FETUS MEMBRANE RUPTURE; PRIORITY JOURNAL; PUERPERIUM; RETINOPATHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UNSPECIFIED SIDE EFFECT; VASCULITIS;

EID: 84867520063     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.12.54     Document Type: Review

References (141)

1. Silva CA, Bonfa E, Ostensen M. Maintenance of fertility in patients with rheumatic diseases needing anti-inflammatory and immunosuppressive drugs. Arthritis Care Res. 62, 1682-1690 (2010).
2. Wallenius M, Skomsvoll JF, Irgens LM et al. Fertility in women with chronic inflammatory arthritides. Rheumatology (Oxford) 50, 1162-1167 (2011).
3. Areskoug-Josefsson K, Oberg U. A literature review of the sexual health of women with rheumatoid arthritis. Musculoeskeletal Care 7, 219-226 (2009).
4. Stone S, Khamashta MA, Nelson-Piercy C. Nonsteroidal anti-inflammatory drugs and reversible female infertility: Is there a link? Drug Saf. 25, 545-551 (2002).
5. Guballa N, Sammaritano L, Schwartzman S, Buyon J, Lockshin MD. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 43, 550-556 (2000).
6. Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid sindrome. Fertil. Steril. 92, 1803-1810 (2009).
7. Andrade RM, McGwin Jr G, Alarcon GS et al. Predictors of post-partum damage accrual in systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (XXXVIII). Rheumatology 45, 1380-1384 (2006).
8. Lockshin MD, Reinitz E, Druzin ML, Murrman M, Estes D. Lupus pregnancy: Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am. J. Med. 77, 893-898 (1984).
9. Mintz G, Nitz J, Gutierrez G et al. Prospective study of pregnancy in systemic lupus erythematosus: Results of a multi-disciplinary approach. J. Rheumatol. 13, 732-739 (1986).
10. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy: The Hopkins lupus pregnancy center experience. Arthritis Rheum. 34, 1538-1545 (1991).
11. Wong KL, Chan FY, Lee XP. Outcome of pregnancy in patients with systemic lupus erythematosus. A prospective study. Arch. Intern. Med. 151, 269-273 (1991).
12. Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. Lupus and pregnancy studies. Arthritis Rheum. 36, 1392-1397 (1993).
13. Ruiz-Irastorza G, Lima F, Alves J et al. Increased rate of lupus flare during pregnancy and the puerperium. Br. J. Rheumatol. 35, 133-138 (1996).
14. Tandon A, Ibanez D, Gladman DD, Urowitz MB. The effect of pregnancy on lupus nephritis. Arthritis Rheum. 50, 3941-3946 (2004).
15. Khamashta MA, Ruiz-Irastorza G, Hughes GRV. Systemic lupus erythematosus flares during pregnancy. Rheum. Dis. Clin. North Am. 23, 15-30 (1997).
16. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D et al. Outcome of planned pregnancies in systemic lupus erythematosus: A prospective study on 62 pregnancies. Br. J. Rheumatol. 36, 772-777 (1997).
17. Clowse ME, Witter FR, Magder LC, Petri M. The impact of increased lupus activity on obstetrical outcomes. Arthritis Rheum. 52, 514-522 (2005).
18. Imbasciati E, Tincani A, Gregorini G et al. Pregnancy in women with pre-existing lupus nephritis: Predictors of fetal and maternal outcome. Nephrol. Dial. Transplant 24, 519-525 (2009).
19. Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 15, 148-155 (2006).
20. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann. Rheum. Dis. 69, 20-28 (2010).
21. Levy RA, Vilela VS, Cataldo MJ et al. Hydroxychloroquine (HCQ) in lupus pregnancy: Double-blind and placebo-controlled study. Lupus 10, 401-404 (2001).
22. Clowse M, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 54, 3640-3647 (2006).
23. Buyon JP, Kalunian KC, Ramsey-Goldman R et al. Assessing disease activity in SLE patients during pregnancy. Lupus 8, 677-684 (1999).
24. Ruiz-Irastorza G, Khamashta MA, Hughes GRV. Heart disease, pregnancy and systemic autoimmune diseases. In: Heart Disease in Pregnancy (2nd Edition). Oakley C, Warnes CA (Eds). Blackwell Publishing, Oxford, UK, 136-150 (2007).
25. Clowse MEB, Jamison M, Myesr E, James AH. A national study of the complications of lupus in pregnancy. Am. J. Obstet. Gynecol. 199, 127.e1-e6 (2008).
26. Yan Yuen S, Krizova A, Ouimet JM, Pope JE. Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: Results from a case control study and literature review. Open Rheumatol. J. 2, 89-98 (2008).
27. Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J. Rheumatol. 38, 1012-1016 (2011).
28. Stagnaro-Green A, Akhter E, Yim C, Davies TF, Magder L, Petri M. Thyroid disease in pregnant women with systemic lupus erythematosus: Increased preterm delivery. Lupus 20, 690-699 (2011).
29. Magid MS, Kaplan C, Sammaritano LR, Peterson M, Druzin ML, Lockshin MD. Placental pathology in systemic lupus erythematosus: A prospective study. Am. J. Obstet. Gynecol. 179, 226-234 (1998).
30. Hayslett JP. The effect of systemic lupus erythematosus on pregnancy and pregnancy outcome. Am. J. Reprod. Immunol. 28, 199-204 (1992).
31. Clowse ME, Magder LS, Witter F, Petri M. Early risk factors for pregnancy loss in lupus. Obstet. Gynecol. 107(2 Pt 1), 293-299 (2006).
32. Vinet E, Clarke AE, Gordon C et al. Decreased live births in women with systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 63, 1068-1072 (2011).
33. Chakravarty EF, Colon I, Langen ES et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am. J. Obstet. Gynecol. 192, 1897-1904 (2005).
34. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin. J. Am. Soc. Nephrol. 5, 2060-2068 (2010).
35. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54, 899-907 (2006).
36. Meis PJ, Goldenberg RL, Mercer BM et al. for the Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. The preterm prediction study: Risk factors for indicated preterm births. Am. J. Obstet. Gynecol. 178, 562-567 (1998).
37. Chen HH, Lin HC, Yeh JC, Chen CP. Renal biopsy in pregnancies complicated by undetermined renal disease. Acta Obstet. Gynecol. Scand. 80, 888-893 (2001).
38. Steen VD. Pregnancy in women with systemic sclerosis. Obstet. Gynecol. 94, 15-20 (1999).
39. Sampaio-Barros PD, Samara AM, Marques Neto JF. Gynaecologic history in systemic sclerosis. Clin. Rheumatol. 19, 184-187 (2000).
40. Chakravarty EF, Khanna D, Chung L. Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease. Obstet. Gynecol. 111, 927-934 (2008).
41. Steen VD. Autoantibodies in systemic sclerosis. Bull. Rheum. Dis. 45, 6-8 (1996).
42. Steen VD. Pregnancy in scleroderma. Rheum. Dis. Clin. North Am. 33, 345-358 (2007).
43. Steen VD. Scleroderma renal crisis. Rheum. Dis. Clin. North Am. 22, 861-878 (1996).
44. Jimenez FX, Simeon CP, Fonollosa V et al. Scleroderma and pregnancy: Obstetrical complications and the impact of pregnancy on the course of the disease. Med. Clin. (Barc.) 113, 761-764 (1999).
45. Wanchu A, Misra R. Pregnancy outcome in systemic sclerosis. J. Assoc. Physicians India 44, 637-640 (1996).
46. Castellino G, Capucci R, Bernardi S et al. Pregnancy in patients with undifferentiated connective tissue disease: A prospective case-control study. Lupus 20, 1305-1311 (2011).
47. Spinillo A, Beneventi F, Ramoni V et al. Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy. Ann. Rheum. Dis. 71, 918-923 (2012).
48. Mosca M, Neri R, Strigini F et al. Pregnancy outcome in patients with undifferentiated connective tissue disease: A preliminary study on 25 pregnancies. Lupus 11, 304-307 (2002).
49. Silva CA, Sultan SM, Isenberg DA. Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. Rheumatology (Oxford) 42, 1168-1172 (2003).
50. Vancsa A, Ponyi A, Constantin T et al. Pregnancy outcome in idiopathic inflammatory myopathy. Rheumatol. Int. 27, 435-439 (2007).
51. Kitridou RC. Pregnancy in mixed connective tissue disease. Rheum. Dis. Clin. North Am. 31, 497-508, vii (2005).
52. Symmons D, Turner G, Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: New estimates for a new century. Rheumatology (Oxford) 41, 793-800 (2002).
53. Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum. Dis. Clin. North Am. 23, 195-212 (1997).
54. Barret JH, Brennan P, Fiddler M, Silman AJ. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a Nationwide Study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum. 42, 1219-1227 (1999).
55. de Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: Results from a nationwide prospective study. Arthritis Rheum. 59, 1241-1248 (2008).
56. de Man YA, Bakker-Jonges LE, Goorbergh CM et al. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy. Ann. Rheum. Dis. 69, 420-423 (2010).
57. Ostensen M. The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. Am. J. Reprod. Immunol. 28, 235-237 (1992).
58. Ostensen M, Fuhrer L, Mathieu R, Seitz M, Villiger PM. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann. Rheum. Dis. 63, 1212-1217 (2004).
59. Oka M. Effect of pregnancy on the onset and course of rheumatoid arthritis. Ann. Rheum. Dis. 12, 227-229 (1953).
60. Iijima T, Tada H, Hidaka Y et al. Prediction of postpartum onset of rheumatoid arthritis. Ann. Rheum. Dis. 57, 460-463 (1998).
61. Drossaers-Bakker KW, Zwinderman AH, Van ZD, Breedveld FC, Hazes JM. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann. Rheum. Dis. 61, 405-408 (2002).
62. Bowden AP, Barrett JH, Fallow H, Silman AJ. Women with inflammatory polyarthritis have babies of lower birth weight. J. Rheumatol. 28, 355-359 (2001).
63. Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Pregnancy complications and delivery practice in women with connective tissue diseases and inflammatory rheumatic disease in Norway. Acta Obstet. Gynecol. Scand. 79, 490-495 (2000).
64. Wolfberg AJ, Lee-Parritz A, Peller AJ, Lieberman ES. Association of rheumatologic disease with preeclampsia. Obstet. Gynecol. 103, 1190-1193 (2004).
65. Lin HC, Chen SF, Chen YH. Increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis: A nationwide population-based study. Ann. Rheum. Dis. 69, 715-717 (2010).
66. Nogaard M, Larsson H, Pedersen L et al. Rheumatoid arthritis and birth outcomes: A Danish and Swedish nationwide prevalence study. J. Intern. Med. 268, 329-337 (2010).
67. de Man YA, Hazes JM, van der Heide H et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: Results of a national prospective study. Arthritis Rheum. 60, 3196-3206 (2009).
68. Belo L, Santos-Silva A, Rocha S et al. Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 123, 46-51 (2005).
69. Seo P. Pregnancy and vasculitis. Rheum. Dis. Clin. N. Am. 33, 299-317 (2007).
70. Ishikawa K, Matsuura S. Occlusive thromboaortopathy (Takayasu's disease) and pregnancy. Clinical course and management of 33 pregnancies and deliveries. Am. J. Cardiol. 50, 1293-1300 (1982).
71. Aso T, Abe S, Yaguchi T. Clinical gynecologic features of pregnancy in Takayasu arteritis. Heart Vessels 7, 125-132 (1992).
72. Matsumura A, Moriwaki R, Numano F. Pregnancy in Takayasu arteritis from the view of internal medicine. Heart Vessels 7, 120-124 (1992).
73. Sharma BK, Jain S, Vasishta K. Outcome of pregnancy in Takayasu arteritis. Int. J. Cardiol. 75(Suppl. 1), S159-S162 (2000).
74. Suri V, Aggarwal N, Keepanasseril A, Chopra S, Vijayvergiya R, Jain S. Pregnancy and Takayasu arteritis: A single centre experience from North India. J. Obstet. Gynaecol. Res. 36, 519-524 (2010).
75. Hernández-Pacheco JA, Estrada-Altamirano A, Valenzuela- Jirón A, Maya-Quiñones JL, Carvajal-Valencia JA, Chacón-Solís AR. Takayasu's arteritis in pregnancy: Report seven cases. Ginecol. Obstet. Mex. 79, 143-151 (2011).
76. Hidaka N, Yamanaka Y, Fujita Y, Fukushima K, Wake N. Clinical manifestations of pregnancy in patients with Takayasu arteritis: Experience from a single tertiary center. Arch. Gynecol. Obstet. 285, 377-385 (2012).
77. Mandal D, Mandal S, Dattaray C et al. Takayasu arteritis in pregnancy: An analysis from eastern India. Arch. Gynecol. Obstet. 285, 567-571 (2012).
78. Martineau M, Haskard DO, Nelson-Piercy C. Behçet's syndrome in pregnancy. Obstet. Med. 3, 2-7 (2010).
79. Jadaon J, Shushan A, Ezra Y, Sela HY, Ozcan C, Rojansky N. Behçet's disease and pregnancy. Acta Obstet. Gynecol. Scand. 84, 939-944 (2005).
80. Bang D, Chun YS, Haam IB et al. The influence of pregnancy on Behcet's disease. Yonsei Med. J. 38, 437-443 (1997).
81. Uzun S, Alpsoy E, Durdu M et al. The clinical course of Behcet's disease in pregnancy: A retrospective analysis and review of the literature. J. Dermatol. 30, 499-502 (2003).
82. Cervera R, Khamashta MA, Font J et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and pattern of disease expression in a cohort of 1.000 patients. Arthritis Rheum. 46, 1019-1027 (2002).
83. Yasuda M, Tkakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet. Gynecol. 86, 555-559 (1995).
84. Yamada H, Atsumi T, Kobashi G et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J. Reprod. Immunol. 79, 188-195 (2009).
85. Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: Analysis of a population-based hospital dataset. BMC Pregnancy Childbirth 9, 11 (2009).
86. do Prado D, Piovesan M, Staub L, Horta L. Association of anticardiolipin antibodies with preeclampsia. Obstet. Gynecol. 116, 1433-1443 (2010).
87. Ruffatti A, Calligaro A, Hoxha A et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res. 62, 302-307 (2010).
88. Bramham K, Hunt BJ, Germain S et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 9, 58-64 (2010).
89. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 844S-886S (2008).
90. Soh M-C, Nelson-Piercy C. The antiphospholipid syndrome in pregnancy. Expert Rev. Obstet. Gynaecol. 5, 741-761 (2010).
91. Branch DW. Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010. Lupus 20, 158-164 (2011).
92. Gordon PA. Congenital heart block: Clinical features and therapeutic approaches. Lupus 16, 642-646 (2007).
93. Hayashi N, Koshiba M, Nishimura K et al. Prevalence of disease specific antinuclear antibodies in general population: Estimates from annual physical examinations of residents of a small town over a 5 year period. Mod. Rheumatol. 18, 153-160 (2008).
94. Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes. Rheum. Dis. Clin. N. Am. 33, 267-285 (2007).
95. Silverman E, Jaeggi E. Non-cardiac manifestations of neonatal lupus erythematosus. Scand. J. Immunol. 72, 223-225 (2010).
96. Jaeggi E Laskin C Hamilton R Kingdom J Silverman E. The importance of the level of maternal anti-RoSSA antibodies as Prognostic Marker Of The Development Of Cardiac Neonatal Lupus Erythematosus A Prospective Study Of 186 Antibody-exposed Fetuses Infants. J. Am. Coll. Cardiol. 55 2778-2784 (2010).
97. Brucato A, Frassi M, Franceschini F et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 women. Arthritis Rheum. 44, 1832-1835 (2001).
98. Moak JP, Barron KS, Hougen TJ et al. Congenital heart block: Development of late-onset cardiomyopathy, a previously underappreciated sequela. J. Am. Coll. Cardiol. 37, 238-242 (2001).
99. Guettrot-Imbert G, Cohen L, Fermont L et al. A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal anti-SSA/Ro and anti-SSB/La antibodies. J. Rheumatol. 38, 378-386 (2011).
100. Sonesson SE. Diagnosing fetal atrioventricular heart blocks. Scand. J. Immunol. 72, 205-212 (2010).
101. Friedman DM, Kim MY, Copel JA, Llanos C, Davis C, Buyon JP. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR interval and dexamethasone evaluation (PRIDE) study. Am. J. Cardiol. 103, 1102-1106 (2009).
102. Tran HB, Cavill D, Buyon JP, Gordon TP. Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies: Comment on the letter by Kaaja and Julkunen. Arthritis Rheum. 50, 337-338 (2004).
103. Friedman DM, Llanos C, Izmirly PM et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 62, 1138-1146 (2010).
104. Pisoni CN, Brucato A, Ruffatti A et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum. 62, 1147-1152 (2010).
105. Makino S, Yonemoto H, Itoh S, Takeda S. Effect of steroid administration and plasmapheresis to prevent fetal congenital heart block in patients with systemic lupus erythematosus and/or Sjögren's syndrome. Acta Obstet. Gynecol. Scand. 86, 1145-1146 (2007).
106. Izmirly PM, Kim MY, Llanos C et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann. Rheum. Dis. 69, 1827-1830 (2010).
107. Izmirly PM, Costedoat-Chalumeau N, Pisoni C et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro associated cardiac manifestations of neonatal lupus. Circulation 126, 76-82 (2012).
108. Østensen M, Khamashta MA, Lockshin M et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther. 8, 209-227 (2006).
109. Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr. Rheumatol. Online J. 7, 9 (2009).
110. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: A meta-analysis. Reprod. Toxicol. 25, 271-275 (2008).
111. Motta M, Ciardelli L, Marconi M et al. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. Am. J. Perinatol. 24, 441-447 (2007).
112. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: A review of the Food and Drug Administration database. J. Rheumatol. 36, 635-641 (2009).
113. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium, BSR Biologics Register. Anti-TNF therapies and pregnancy: Outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann. Rhuem. Dis. 70, 823-826 (2011).
114. Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum. 61, 587-592 (2009).
115. Zelinkova Z, de Haar C, de Ridder L et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment. Pharmacol. Ther. 33, 1053-1058 (2011).
116. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: Evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin. Gastroenterol. Hepatol. 4, 1255-1258 (2006).
117. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J. Clin. Gastroenterol. 43, 613-616 (2009).
118. Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: Drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann. Rheum. Dis. 68, 1793-1794 (2009).
119. Ben-Horin S, Yavzori M, Katz L et al. Adalimumab level in breast milk of a nursing mother. Clin. Gastroenterol. Hepatol. 8, 475-476 (2010).
120. Wolf D, Mahadevan U. Certolizumab pegol use in pregnancy: Low levels detected in cord blood. American College of Rheumatology (ACR). Arthritis Rheum. 62, Abstract 718 (2010).
121. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 117, 1499-1506 (2011).
122. Fischer-Betz R, Specker C, Schneider M. Successful outcome of two pregnancies in patients with adult-onset Still's disease treated with IL-1 receptor antagonist (anakinra). Clin. Exp. Rheumatol. 29, 1021-1023 (2011).
123. Berger CT, Recher M, Steiner U, Hauser TM. A patient's wish: Anakinra in pregnancy. Ann. Rheum. Dis. 68, 1794-1795 (2009).
124. Benlysta® (Belimumab), package insert. Human Genome Sciences and GlaxoSmithKline, NC, USA.
125. von Dadelszen P, Dwinnell S, Magee LA et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 118, 624-628 (2011).
126. Bendayan D, Hod M, Oron G et al. Pregnancy outcome in patients with pulmonary arterial hypertension receiving prostacyclin therapy. Obstet. Gynecol. 106, 1206-1210 (2005).
127. Moretti ME, Caprara D, Drehuta I et al. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet. Gynecol. Int. 2012, 658310 (2012).
128. Boix E, Zapater P, Picó A, Moreno O. Teratogenicity with angiotensin II receptor antagonists in pregnancy. J. Endocrinol. Invest. 28, 1029-1031 (2005).
129. Li DK, Yang C, Andrade S, Tavares V, Ferber Jr. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: A retrospective cohort study. BMJ 18, 343 d5931 (2011).
130. Stathopoulos IP, Liakou CG, Katsalira A et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens) 10, 280-291 (2011).
131. Kumasawa K, Ikawa M, Kidoya H et al. Pravastatin induces placental growth factor (PGF) and ameliorates pre-eclampsia in a mouse model. Proc. Natl Acad. Sci. USA 108, 1415-1415 (2011).
132. Seshadri S, Oakeshott P, Nelson-Piercy C, Chappell L. Prepregnancy care. BMJ 31, 344 e3467 (2012).
133. Cnossen JS, Morris RK, ter Riet G et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: A systematic review and bivariable meta-analysis. CMAJ 178, 701-711 (2008).
134. Duley L, Henderson-Smart DJ, Meher S et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. 2, CD004659 (2007).
135. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst. Rev. 8, CD001059 (2010).
136. Horlocker T, Wedel D, Rowlingson J, Enneking F, American College of Chest Physicians. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence- Based Guidelines (Third Edition). Reg. Anesth. Pain Med. 35, 64-101 (2010).
137. Kestelman P, Trussell J. Efficacy of the simultaneous use of condoms and spermicides. Fam. Plann. Perspect. 23(5), 226-227, 232 (1991).
138. Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353, 2550-2558 (2005).
139. Chabbert-Buffet N, Amoura Z, Scarabin PY et al. Pregnane progestin contraception in systemic lupus erythematosus: A longitudinal study of 187 patients. Contraception 83, 229-237 (2011).
140. Gai L, Zhang J, Zhang H, Gai P, Zhou L, Liu Y. The effect of depot medroxyprogesterone acetate DMPA on bone mineral density BMD and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age. Contraception 83, 218-222 (2011).
141. Clowse MEB. Managing contraception and pregnancy in the rheumatologic diseases. Best Pract. Res. Clin. Rheumatol. 24, 373-385 (2010).